Article Information
History
- August 25, 2021.
Article Versions
- You are currently viewing Version 1 of this article (August 25, 2021 - 09:37).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Thiago Cerqueira-Silva1,2,
- Vinicius de Araújo Oliveira, M.D.1,2,3,
- Julia Pescarini, Ph.D.3,4,
- Juracy Bertoldo Júnior2,3,
- Tales Mota Machado5,
- Renzo Flores Ortiz, Ph.D3,
- Gerson Penna, M.D., Ph.D.6,
- Maria Yury Ichihara, M.D., Ph.D.3,
- Jacson Venâncio de Barros7,
- Viviane S. Boaventura, M.D., Ph.D.1,2,
- Mauricio L. Barreto, M.D., Ph.D.2,3,
- Guilherme Loureiro Werneck, M.D., Ph.D.8 and
- Manoel Barral-Netto, M.D., Ph.D.1,2,3,*
- 1LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
- 2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
- 3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
- 4London School of Hygiene and Tropical Medicine, London, United Kingdom
- 5Universidade Federal de Ouro Preto, Ouro Preto, Brazil
- 6Núcleo de Medicina Tropical, Universidade de Brasília. Escola Fiocruz de Governo, Fiocruz Brasilia. Brasilia, DF, Brazil
- 7Department of Health Informatics, Ministry of Health, Brasília, Brazil
- 8Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
- ↵*Corresponding author: Manoel Barral-Netto, MD manoel.barral{at}fiocruz.br
Posted August 25, 2021.
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)
